UT Austin joins $11.6 million Defense Department trial of SAINT brain stimulation for postpartum depression
A multi-site study expands testing of a rapid, non-drug approach for a high-risk perinatal mental health condition
The University of Texas at Austin has joined a nationwide, Department of Defense-funded clinical trial evaluating whether a rapid, non-drug brain stimulation protocol can safely reduce symptoms of postpartum depression. The four-site study is supported by $11.6 million in federal funding and is now underway, with UT Austin selected as one of the participating research locations.
The trial is testing SAINT neuromodulation, a form of transcranial magnetic stimulation (TMS) that uses MRI-guided targeting and an accelerated treatment schedule. SAINT is already cleared by the U.S. Food and Drug Administration for major depressive disorder in adults who have not had satisfactory improvement with antidepressant medications during their current episode. The postpartum depression trial is designed to determine whether the same approach can be applied safely and effectively during the months following childbirth.
How SAINT differs from standard TMS
TMS is a noninvasive technique that uses magnetic pulses delivered through a coil placed against the scalp to stimulate specific brain regions associated with mood regulation. Standard TMS is typically delivered once daily over several weeks. SAINT compresses treatment into five consecutive days and combines high-frequency dosing with individualized targeting based on brain imaging.
In earlier peer-reviewed studies of treatment-resistant depression, SAINT-related protocols were associated with rapid symptom improvement and higher remission rates than sham stimulation in controlled settings. Those findings informed FDA clearance for major depressive disorder; however, postpartum depression is a distinct clinical context, and the current trial is structured to evaluate outcomes specifically for patients after delivery.
Trial design, timelines, and what participation may involve
The study is a randomized controlled trial, a design intended to compare active stimulation with a control condition while minimizing bias. At UT Austin, recruitment information indicates treatment is delivered over five consecutive days and may involve extended daily time commitments, alongside MRI scans and repeated clinical assessments to measure symptom change.
Eligibility criteria described for the UT Austin site include adults who have given birth within the previous 12 months and are experiencing postpartum depression, with additional screening related to MRI compatibility and safety factors commonly used in brain-stimulation research.
Why the Department of Defense is funding postpartum depression research
Postpartum depression is a serious mood disorder that can affect functioning, bonding, and family stability. A fast-acting, non-drug treatment could be particularly relevant for patients who need rapid relief, want to avoid medication exposure during breastfeeding, or have not improved with first-line approaches. The trial’s Defense Department backing reflects broader federal interest in scalable mental health interventions that can be deployed across diverse populations, including military families.
What the trial can and cannot conclude
The study is designed to determine whether SAINT neuromodulation can be used safely and effectively for postpartum depression, not to establish it as a standard treatment before results are available. Researchers will evaluate symptom change, tolerability, and safety, with the goal of producing evidence that could guide future clinical practice and regulatory decisions for postpartum indications.